Caroline McCoach, MD, PhD

Title(s)Assistant Clinical Professor, Medicine
SchoolSchool of Medicine
Phone415-885-3882
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford University, Stanford, CAPhD2005Biochemistry
    University of Colorado, Aurora, COMD2009
    University of California, Davis, Sacramento, CAResidency/ Chief Residency2013
    University of California, Davis, Sacramento, CAResearch Fellowship2014
    University of Colorado, Aurora, COClinical Fellowship2017

    Collapse Overview 
    Collapse Overview
    Caroline McCoach is a thoracic oncologist who focuses on the treatment of patients with lung cancer as well as other thoracic malignancies. Her goal is to provide a personalized approach to treatment, based on each patient’s cancer type in combination with their individual treatment goals.

    Her primary research focus is on treatment of cancers driven by genetic mutations or alterations such as ALK, ROS1, EGFR, and others. She is also working to find treatments to prevent or delay the development of resistance to targeted therapies as well as increase the efficacy of standard targeted therapies by using rational combination treatments. She works closely with laboratory based researchers to develop new and improved treatments for lung cancer patients.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial. Oncologist. 2021 Sep 15. Minchom A, Tan AC, Massarelli E, Subbiah V, Boni V, Robinson B, Wirth LJ, Hess LM, Jen MH, Kherani J, Olek E, McCoach CE. PMID: 34523767.
      View in: PubMed   Mentions:    Fields:    
    2. Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial. Oncologist. 2021 Sep 13. Wirth LJ, Robinson B, Boni V, Tan DSW, McCoach C, Massarelli E, Hess LM, Jen MH, Kherani J, Olek E, Subbiah V. PMID: 34516023.
      View in: PubMed   Mentions:    Fields:    
    3. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Br J Cancer. 2021 Sep 03. Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR. PMID: 34480094.
      View in: PubMed   Mentions:    Fields:    
    4. Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. J Thorac Oncol. 2021 Aug 26. Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C, Sinha S, Pollom EL, Nagpal S, Camidge DR, Rusthoven CG, Braunstein SE, Wakelee HA, McCoach CE. PMID: 34455066.
      View in: PubMed   Mentions:    Fields:    
    5. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 2021 Jun 24; 22(8):72. Sun F, McCoach CE. PMID: 34165651.
      View in: PubMed   Mentions:    Fields:    
    6. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res. 2021 Aug 01; 27(15):4160-4167. Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A. PMID: 34088726.
      View in: PubMed   Mentions: 1     Fields:    
    7. A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. NPJ Precis Oncol. 2021 May 17; 5(1):41. Gurule NJ, McCoach CE, Hinz TK, Merrick DT, Van Bokhoven A, Kim J, Patil T, Calhoun J, Nemenoff RA, Tan AC, Doebele RC, Heasley LE. PMID: 34001994.
      View in: PubMed   Mentions:
    8. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. J Thorac Oncol. 2021 06; 16(6):1030-1041. Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW, Diehn M, Han SS, Wakelee HA. PMID: 33588109.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021; 1. McCoach CE, Yu A, Gandara DR, Riess JW, Vang DP, Li T, Lara PN, Gubens M, Lara F, Mack PC, Beckett LA, Kelly K. PMID: 34036220.
      View in: PubMed   Mentions:
    10. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol. 2020 12; 31(12):1725-1733. Lin JJ, Liu SV, McCoach CE, Zhu VW, Tan AC, Yoda S, Peterson J, Do A, Prutisto-Chang K, Dagogo-Jack I, Sequist LV, Wirth LJ, Lennerz JK, Hata AN, Mino-Kenudson M, Nardi V, Ou SI, Tan DS, Gainor JF. PMID: 33007380.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    11. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 08 27; 383(9):813-824. Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. PMID: 32846060.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    12. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. 2020 09 03; 182(5):1232-1251.e22. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG. PMID: 32822576.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    13. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. J Thorac Oncol. 2020 10; 15(10):1611-1623. Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ignatius Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE. PMID: 32540409.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    14. Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies. Clin Cancer Res. 2020 07 15; 26(14):3499-3500. Blakely CM, McCoach CE. PMID: 32366673.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. J Thorac Dis. 2020 May; 12(5):2896-2909. Velazquez AI, McCoach CE. PMID: 32642202.
      View in: PubMed   Mentions:
    16. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 01 15; 26(2):439-449. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. PMID: 31548343.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    17. Engineering Multidimensional Evolutionary Forces to Combat Cancer. Cancer Discov. 2019 05; 9(5):587-604. McCoach CE, Bivona TG. PMID: 30992280.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    18. A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy. J Thorac Oncol. 2019 01; 14(1):8-10. McCoach CE. PMID: 30579546.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Res. 2019 02 01; 79(3):546-556. Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG. PMID: 30538120.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    20. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clin Lung Cancer. 2019 03; 20(2):e137-e141. Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. PMID: 30553716.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    21. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018 Dec; 13(12):1818-1831. Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. PMID: 30268698.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    22. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer. 2018 11; 19(6):531-543. Hanna RF, Ward TJ, Chow DS, Lagana SM, Moreira RK, Emond JC, Weintraub JL, Prince MR, Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele RC, Camidge DR. PMID: 30197261; PMCID: PMC6204301.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018 09; 20(9):1064-1073. Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG. PMID: 30104724.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansAnimalsCells
    24. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res. 2018 07 15; 24(14):3334-3347. McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC. PMID: 29636358.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    25. Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 06 15; 24(12):2758-2770. McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC. PMID: 29599410.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    26. The evolving understanding of immunoediting and the clinical impact of immune escape. J Thorac Dis. 2018 Mar; 10(3):1248-1252. McCoach CE, Bivona TG. PMID: 29708132.
      View in: PubMed   Mentions:
    27. The importance of the initial response to cancer treatment in predicting longer overall survival. Expert Rev Clin Pharmacol. 2018 02; 11(2):109-111. McCoach CE, Doebele RC. PMID: 29251525.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. PMID: 29106415.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansCells
    29. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol. 2017 Nov 01; 28(11):2707-2714. McCoach CE, Blumenthal GM, Zhang L, Myers A, Tang S, Sridhara R, Keegan P, Pazdur R, Doebele RC, Kazandjian D. PMID: 29045514.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    30. PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Non-Small Cell Lung Cancer: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S313. Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele R, Camidge DR. PMID: 27969535.
      View in: PubMed   Mentions:
    31. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations. Drugs Today (Barc). 2016 Oct; 52(10):561-568. McCoach CE, Jimeno A. PMID: 27910964.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    32. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clin Lung Cancer. 2016 09; 17(5):466-469. McCoach CE, Bivona TG, Blakely CM, Doebele RC. PMID: 27378174.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    33. A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry. J Thorac Oncol. 2016 Mar; 11(3):407-13. McCoach CE, Berge EM, Lu X, Barón AE, Camidge DR. PMID: 26725180.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    34. Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer. Cancer Treat Commun. 2015; 4:15-18. McCoach CE, Rogers JG, Dwyre DM, Jonas BA. PMID: 25932381.
      View in: PubMed   Mentions:
    35. The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol. 2014 Dec; 15(4):644-57. McCoach CE, Doebele RC. PMID: 25228144.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    36. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014 Apr 10; 3(2):e000697. Armstrong EJ, Chen DC, Westin GG, Singh S, McCoach CE, Bang H, Yeo KK, Anderson D, Amsterdam EA, Laird JR. PMID: 24721799.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    37. Treatment paradigms in advanced non-small-cell lung cancer. Clin Adv Hematol Oncol. 2013 Oct; 11(10):629-39. McCoach CE, Kelly K. PMID: 24518373.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    38. Fungating mass as first presentation of advanced breast cancer. J Gen Intern Med. 2014 Apr; 29(4):685. McCoach CE, Aronowitz P. PMID: 24065379.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Gender-related variation in the clinical presentation and outcomes of critical limb ischemia. Vasc Med. 2013 Feb; 18(1):19-26. McCoach CE, Armstrong EJ, Singh S, Javed U, Anderson D, Yeo KK, Westin GG, Hedayati N, Amsterdam EA, Laird JR. PMID: 23439776.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    40. Systematic identification of balanced transposition polymorphisms in Saccharomyces cerevisiae. PLoS Genet. 2009 Jun; 5(6):e1000502. Faddah DA, Ganko EW, McCoach C, Pickrell JK, Hanlon SE, Mann FG, Mieczkowska JO, Jones CD, Lieb JD, Vision TJ. PMID: 19503594.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    41. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int. 2009 Jun; 103(12):1729-37. Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. PMID: 19220256.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells